Traws Pharma vs Tvardi Therapeutics
TRAW and TVRD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TRAW and TVRD compare
Tvardi Therapeutics is the larger company, worth 4.1 times as much as Traws Pharma ($15.7M against $3.9M).
Tvardi Therapeutics scores higher on the StockData Score (6 against 5 for Traws Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TRAW | TVRD |
|---|---|---|
| Size and price | ||
| Market cap | $3.9M | $15.7M |
| Share price | $0.251 | $1.18 |
| Change, 1 year | −88.3% | −72.2% |
| Change, 5 years | −99.7% | −99.8% |
| Beta (5Y) | 1.19 | 1.11 |
| Employees | 7 | 12 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 1.0× |
| Growth | ||
| Revenue growth, 5Y average | 64.6% | – |
| Profitability | ||
| Return on equity | – | −123% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.93 | 2.86 (better) |
| Altman Z-score | −85.39 | −9.66 (better) |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | −109% | – |
| Shareholder yield | −109% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 40.1% | 16.7% |
| Held by insiders | 35.7% | 15.6% |
| Insider net buying, 12 months | $998K | – |
| Short interest, % of float | 6.9% | 2.7% |
Go deeper
- TRAW stock overview
- TRAW income statement
- TRAW valuation and score
- TVRD stock overview
- TVRD income statement
- TVRD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.